Related Experiment Videos
Discovery of new anti-cancer agents
M W Lobbezoo1, M R Krul, H M Pinedo
1NDDO Oncology, Amsterdam.
Abstract:
Anticancer drug discovery has changed fundamentally owing to recent progress in basic research. Historically, the discovery of potential new drugs for the treatment of cancer has largely relied on large-scale random screening. Although several useful agents have become available, sometimes after the development of chemical analogues of the original OhitO, this approach has generally been disappointing in terms of the efficacy/toxicity balance. To date, a range of cancer-specific molecular and biological drug targets are available providing opportunities for the design and discovery of specific anti-cancer agents with better tumour selectivity, and therefore less toxicity, than conventional agents. Among the many innovative approaches currently explored in pre-clinical and clinical research and development programs are inhibition of angiogenesis and metastasis, tumour vaccines/immunotherapy and gene therapy approaches. Several promising drug development projects are currently underway in these areas. The advent of innovative anticancer agents also has important consequences for the organisation of new drug development. Traditional drug development methodologies are often not appropriate for agents having completely new modes of action. The design of new drug development templates for such agents therefore has high priority in anti-cancer drug development organisations.
Insights
Cancer drug discovery is shifting from random screening to targeted therapies. New approaches like immunotherapy and gene therapy offer improved efficacy and reduced toxicity for novel anticancer agents.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Traditional large-scale random screening for anticancer drugs has yielded limited success, often with poor efficacy/toxicity balance.
- Recent advancements in basic cancer research provide novel molecular and biological targets for drug development.
- Existing anticancer agents sometimes require chemical analogue development, which can be time-consuming and inefficient.
Purpose of the Study:
- To highlight the paradigm shift in anticancer drug discovery towards targeted therapies.
- To discuss innovative approaches like angiogenesis inhibition, immunotherapy, and gene therapy.
- To emphasize the need for new drug development frameworks for novel anticancer agents.
Main Methods:
- Review of current pre-clinical and clinical research in anticancer drug development.
- Analysis of the limitations of traditional drug screening methodologies.
- Exploration of emerging therapeutic strategies targeting specific cancer pathways.
Main Results:
- Identification of numerous cancer-specific molecular and biological targets.
- Development of innovative therapeutic strategies including angiogenesis and metastasis inhibition, tumor vaccines, immunotherapy, and gene therapy.
- Recognition of promising drug development projects in these novel areas.
Conclusions:
- Anticancer drug discovery is increasingly reliant on understanding cancer biology for targeted agent design.
- Novel therapeutic approaches offer the potential for improved tumor selectivity and reduced toxicity compared to conventional agents.
- Adaptation of drug development methodologies is crucial for agents with new mechanisms of action to ensure successful translation to clinical practice.